- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 11, Issue 27, 2005
Current Pharmaceutical Design - Volume 11, Issue 27, 2005
Volume 11, Issue 27, 2005
-
-
Melanoma Immunotherapy: Past, Present, and Future
Authors: F. Saleh, W. Renno, I. Klepacek, G. Ibrahim, S. Asfar, H. Dashti, P. Romero, A. Dashti and A. BehbehaniThe incidence of cancer and its related morbidity and mortality remain on the increase in both developing and developed countries. Cancer remains a huge burden on the health and social welfare sectors worldwide and its prevention and cure remain two golden goals that science strives to achieve. Among the treatment options for cancer that have emerged in the past 100 years, cancer vaccine immunotherapy seems to Read More
-
-
-
Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Authors: G. Sauer, C. Kurzeder, Heilmann Heilmann, R. Kreienberg and H. DeisslerBesides the traditional therapeutic options, treatment with antibodies specific for the receptor tyrosine kinase HER-2/neu has been established as a standard therapy in the clinical management of advanced breast cancer. Ongoing clinical studies focus on the improvement of application protocols in order to minimize side effects and evaluate the potential therapeutic benefit of anti-HER-2/neu antibodies in combination wit Read More
-
-
-
Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Authors: A. D. Santin, S. Bellone, J. J. Roman, A. Burnett, M. J. Cannon and S. PecorelliHuman papillomavirus (HPV) infection represents the most important risk factor for the development of cervical dysplasia and cervical cancer. Several lines of evidence suggest that cell-mediated immune responses are important in controlling both HPV infections and HPV-associated neoplasia. Since HPV E6 and E7 oncoproteins are expressed in these lesions and are necessary for the maintenance of the malignant ph Read More
-
-
-
Immunity to Tumour Antigens
Authors: G. Li, S. A. Ali, S. E.B. McArdle, S. Mian, M. Ahmad, A. Miles and R. C. ReesDuring the last decade, a large number of human tumour antigens have been identified. These antigens are classified as tumour-specific shared antigens, tissue-specific differentiation antigens, overexpressed antigens, tumour antigens resulting from mutations, viral antigens and fusion proteins. Antigens recognised by effectors of immune system are potential targets for antigen-specific cancer immunotherapy. However Read More
-
-
-
Use of Cytokines in Cancer Vaccines/Immunotherapy: Recent Developments Improve Survival Rates for Patients with Metastatic Malignancy
Authors: S. Dezfouli, I. Hatzinisiriou and S. J. RalphHistorically, patients with disseminated cancer have had poor prognoses and chemotherapy has been of little benefit. However, several different avenues of clinical research are providing reasons for hope. The advent of cytokine immunotherapy, particularly in combination with chemotherapy (biochemotherapy) has seen significantly improved outcomes for metastatic disease. Early biochemotherapy trials often revealed more Read More
-
-
-
Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Authors: F. Saleh, I. Klepacek, G. Ibrahim, H. Dashti, S. Asfar, A. Behbehani, H. Al-Sayer and A. DashtiTo develop an effective pharmaceutical treatment for a disease, we need to fully understand the biological behavior of that disease, especially when dealing with cancer. The current available treatment for cancer may help in lessening the burden of the disease or, on certain occasions, in increasing the survival of the patient. However, a total eradication of cancer remains the researchers' hope. Some of the discoveries in t Read More
-
-
-
Why Drugs Fail - A Study on Side Effects in New Chemical Entities
Authors: D. Schuster, C. Laggner and T. LangerOur study focuses on the reasons for market withdrawals of drugs and drug development project terminations in clinical phases I-III from 1992 to 2002. Over 90% of the market withdrawals were caused by drug toxicity. Hepatotoxicity and cardiovascular toxicity proved to be the major causes for two out of three market withdrawals in the respective time period. In clinical phases I-III 43% of drug development project terminatio Read More
-
-
-
Dopamine-Glutamate Interaction and Antipsychotics Mechanism of Action: Implication for New Pharmacological Strategies in Psychosis
Authors: A. de Bartolomeis, G. Fiore and F. IasevoliSchizophrenia is a severe mental illness characterized by behavioral and cognitive symptoms. Several lines of evidence focus on a direct involvement of the glutamatergic system in the pathophysiology of psychosis. The hypofunction of the ionotropic glutamate N-methyl-D-Aspartate Receptor (NMDA-R) has been proposed as a model of schizophrenia in humans. Cortical and subcortical glutamate release seems to be Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
